Enekinragene Inzadenovec (PCRX-201)

Phase 2Biologic

Enekinragene Inzadenovec (PCRX-201) is one of 3 biologic programs targeting Osteoarthritis (OA) of the Knee. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Osteoarthritis (OA) of the KneeRecruiting

Osteoarthritis (OA) of the KneePhase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Osteoarthritis (OA) of the Knee

#DrugCompanyPhaseTrials

Glucophage

EMD Serono

Phase 1

1 2

Glucagon-Like Peptide-1 Receptor Agonists

Bayer

Phase 1

1 3

Enekinragene Inzadenovec (PCRX-201)

Pacira Pharmaceuticals, Inc

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2032

Phase 2Recruiting

Osteoarthritis (OA) of the Knee

NCT06884865

Clinical

Trials by Indication[1]

Osteoarthritis (OA) of the Knee1 trial

A Phase 2, Two-Part, Randomized, Double-Blind, Active-Controlled Study to Assess the Safety and Tolerability of Enekinragene Inzadenovec (PCRX-201) in Subjects With Painful Osteoarthritis of the Knee

Recruiting· Pacira Pharmaceuticals, Inc logo

Pacira Pharmaceuticals, Inc·Phase 2·NCT06884865·135 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Enekinragene Inzadenovec (PCRX-201). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Enekinragene Inzadenovec (PCRX-201) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Enekinragene Inzadenovec (PCRX-201). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pacira Pharmaceuticals, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Pacira Pharmaceuticals, Inc

Enekinragene Inzadenovec (PCRX-201)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2032

Trials by Indication[1]

Osteoarthritis (OA) of the Knee1 trial

References

Drug Info

Quick Facts

Related News